Every 8-K that Alignment Healthcare, Inc. (ALHC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ALHC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALHC filings page.
Alignment Healthcare reported results for the quarter ended June 30, 2026, with total revenue of $1,335.6 million, up 31.6% year-over-year, and health plan membership of approximately 294,100, up 31.5%. The company stated that performance surpassed the high end of its guidance across key metrics.
Adjusted gross profit was $182.9 million, up 35.3%, and income from operations was $42.1 million. Medical benefits ratio based on adjusted gross profit was 86.3%, improving about 40 basis points year-over-year. Adjusted EBITDA was $68.1 million, reflecting a 5.1% margin, while net income increased to $36.6 million from $15.7 million.
For the third quarter of 2026, the company forecasts revenue between $1,300 million and $1,320 million and adjusted EBITDA between $20 million and $30 million. For full-year 2026, revenue guidance is $5,195 million to $5,225 million and adjusted EBITDA guidance is $145 million to $163 million, alongside higher expected membership and adjusted gross profit.
Alignment Healthcare, Inc. reported the results of its virtual annual stockholder meeting held on June 4, 2026. Stockholders representing 194,112,992 shares of common stock were present or represented by proxy.
All three Class II director nominees — Jody Bilney, David Hodgson, and Jacqueline Kosecoff — were elected to three-year terms ending at the 2029 annual meeting. Stockholders also ratified the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, on an advisory basis, stockholders approved the compensation of the company’s named executive officers in the say-on-pay vote.
Alignment Healthcare, Inc. reported governance and leadership changes. On May 6, 2026, its board amended the Amended and Restated Bylaws to formally add the position of Vice Chair of the Board, who presides over board meetings when the Chairman is absent.
Founder and CEO John Kao has been named Chairman of the Board while continuing as CEO, keeping strategic leadership centralized. Former Chairman Joseph Konowiecki becomes Vice Chairman and Executive Vice President of Corporate Affairs, overseeing Human Resources, Legal and Communications. Mark Kent joins as President of the Management Services Organization, and Shane Hochradel becomes Chief Operations Officer, both reporting to Kao.
Alignment Healthcare, Inc. reported strong results for the first quarter ended March 31, 2026, highlighted by rapid growth and a return to profitability. Total revenue reached $1,235.2 million, up 33.3% year-over-year, driven by Medicare Advantage expansion.
Health plan membership rose to approximately 284,800 members, a 30.9% increase. Adjusted gross profit was $145.9 million, up 36.1%, and income from operations was $15.5 million. The medical benefits ratio based on adjusted gross profit improved to 88.2%, reflecting better cost control.
Adjusted EBITDA was $37.9 million with a 3.1% margin, up 87.6% year-over-year, while net income was $11.4 million, compared to a $9.4 million net loss a year earlier. For 2026, the company guides to revenue of $5,160–$5,205 million and adjusted EBITDA of $138–$163 million, along with continued membership growth.
Alignment Healthcare, Inc. disclosed that a selling stockholder entered into an underwriting agreement with J.P. Morgan Securities LLC for an underwritten public offering of 13,167,733 shares of its common stock. The sale closed on March 4, 2026, and the company will not receive any proceeds.
The transaction was conducted under an automatically effective Form S-3ASR shelf registration statement filed on March 2, 2026, using a base prospectus and a filed prospectus supplement. The agreement includes customary representations, covenants and indemnification, and the filing attaches the underwriting agreement and related legal opinion as exhibits.
Alignment Healthcare, Inc. reported strong fourth quarter and full-year 2025 results, beating the high end of its guidance across membership, revenue, adjusted gross profit and adjusted EBITDA. Full-year revenue reached $3.95 billion, up 46.1% year-over-year, with a medical benefits ratio of 87.5%.
Adjusted EBITDA for 2025 was $109.9 million, and income from operations turned positive at $14.8 million while net loss narrowed to $1.0 million. The company guided 2026 revenue to $5.14–$5.19 billion, implying about 30%–31% growth, and expects adjusted EBITDA of $133–$163 million. Year-end cash and cash equivalents were $575.8 million, supported by $139.9 million of operating cash flow in 2025.
Alignment Healthcare, Inc. used a current report to update its growth outlook and reaffirm guidance. The company estimates about 275,300 health plan members as of January 1, 2026, which it states is roughly 31% growth versus January 1, 2025. It also expects 290,000 to 296,000 members by December 31, 2026, or about 24% to 27% growth relative to the midpoint of its latest 2025 year-end membership guidance.
The company also says current consensus for 2026 adjusted EBITDA of approximately $145 million will fall within its planned full-year 2026 guidance range, which it intends to provide with its fourth-quarter 2025 earnings. For 2025, it reaffirms prior guidance, including health plan membership of 232,500 to 234,500, revenue of $3,931 million to $3,946 million, adjusted gross profit of $474 million to $483 million, and adjusted EBITDA of $90 million to $98 million.
Alignment Healthcare, Inc. furnished a Form 8-K to announce it issued a press release with financial results for its third quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The information under Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference into other filings unless expressly stated.
Alignment Healthcare, Inc. is meeting with investors and analysts on September 9–10, 2025 to discuss its business strategy, competitive position in the Medicare Advantage market, and recent operating results. The company also plans to review preliminary Centers for Medicare & Medicaid Services Medicare Advantage Star ratings for rating year 2026 and payment year 2027.
Based on an early look at the data, Alignment Healthcare will reaffirm its expectation that approximately 100% of its membership will be enrolled in plans rated 4 Stars or higher, which is an important quality benchmark in Medicare Advantage. The company reminds readers that this expectation is forward-looking and subject to risks, including its ability to maintain high Star ratings, navigate regulatory requirements, manage provider relationships, and address labor and other operational challenges.